secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K/A
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001140361-25-000467
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics files audited FY2023 financials of acquired Opus Inc.; net loss $9.75M, cash $180k
--------------------------------------------------------------------------------

- FY2023 audited: net loss $9.75M, no revenue; accumulated deficit $25.1M.
- Cash & equivalents only $0.18M at Dec 31, 2023; total liabilities $2.93M exceed assets $0.79M.
- R&D spending $7.18M, G&A $2.72M; convertible notes and warrant liabilities of $1.12M at fair value.
- Acquisition closed Oct 22, 2024; combined company renamed Opus Genetics, Inc. (ticker IRD).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125000467/0001140361-25-000467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125000467/ef20041180_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer